- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05960617
Efficacy and Safety of Empagliflozin in GSD-Ib Patients
Efficacy and Safety of Empagliflozin in Patients With Glycogen Storage Disease Type Ib
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Glycogen storage disease type Ib (GSD-Ib) is a type of genetic disease with a prevalence of approximately 1 in 500,000. In addition to phenotypes common to GSD-I such as hypoglycemia, hypoglycemia, lactatemia, hyperlipidemia, hyperuricemia, and hepatomegaly, GSD-Ib patients also experience neutropenia and dysfunction, causing infections and inflammatory bowel disease (IBD). At present, the only available treatment for neutropenia in GSD-Ib patients is subcutaneous injection of granulocyte-colony stimulating factor (G-CSF). G-CSF increases the number of neutrophils, but does not improve neutrophil dysfunction, and is also associated with the risk of concurrent splenomegaly and malignancy.
The most recent research findings demonstrated that substantial accumulation of 1,5-anhydroglucitol-phosphate is the cause of neutropenia and neutrophil dysfunction in GSD Ib patients. Empagliflozin, an SGLT2 inhibitor, is an efficient and secure approach of treating neutropenia in these patients by inhibiting renal glucose and 1,5-anhydroglucitol reabsorption. Our study's objective is to assess the efficacy and safety of empagliflozin (Jardiance®) in patients with GSD Ib.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Wenjuan Qiu, MD PhD
- Phone Number: +86-21-25076466
- Email: qiuwenjuan@xinhuamed.com.cn
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200092
- Recruiting
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
-
Contact:
- Wenjuan Qiu, MD PhD
- Phone Number: +86-21-25076466
- Email: qiuwenjuan@xinhuamed.com.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with glycogen storage disease type Ib (genetically diagnosed) aged ≥ 1 year and ≤ 50 years;
- Patients meet the diagnostic criteria for Crohn's disease (CD) based on Expert consensus on the diagnosis and treatment of inflammatory bowel disease in Chinese children (2019) or Consensus opinion on the diagnosis and treatment of inflammatory bowel disease in China (2018), or patients meet the diagnostic criteria for recurrent respiratory tract infection based on Clinical diagnosis and treatment for recurrent respiratory tract infection in Chinese children (2022);
- Subjects and their guardians/clients (< 18 years old) or subjects (≥ 18 years old) signed the informed consent form.
Exclusion Criteria:
- Patients with chronic kidney disease (eGFR < 60 ml/min/1.73 m^2) or cirrhosis (Metavir F4);
- Experiencing symptomatic or severe hypoglycemia within 1 month before the start of this trial;
- Absolute neutrophil count continued ≥ 1.5 × 10^9/L (≥ 3 tests, each interval ≥ 5 days);
- Current active urinary tract infection (until urine routine twice negative);
- Participating other clinical investigators in the past 1 month;
- Pregnancy, breast-feeding and having a pregnancy plan;
- Presence of contraindications to empagliflozin therapy (hypersensitivity to empagliflozin, current or history of gangrene, history of recurrent urinary or genital infections);
- Patients who are not suitable for participating in the clinical investigator or with low compliance in the investigator 's opinion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Oral administration of Empagliflozin
All subjects will have a baseline assessment and be prospectively followed up for 12 months to examine their outcome after receiving empagliflozin.
|
Oral administration of Empagliflozin: The starting dose was 0.3 mg/kg/day in 2 divided doses for 3 months. If the subject had an absolute neutrophil count > 1.0 × 10^9/L and clinical improvement (decreased number of infections and/or decreased IBD activity within 3 months), the maintenance dose was maintained. If the subject had an absolute neutrophil count < 1.0 × 10^9/L but clinical improvement (decreased number of infections and/or decreased IBD activity within 3 months), the maintenance dose was maintained and reassessed 1 month later. If the subject had an absolute neutrophil count < 1.0 × 10^9/L and no clinical improvement (no change in number of infections and/or no change in IBD activity within 3 months), the dose was increased by 0.1 mg/kg/day and reassessed 3 months later. Assessments were then performed every 3 months with the same dose modification criteria as above.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in Absolute neutrophil count at 1 year
Time Frame: 1 year
|
Efficacy of Empaglifozin measured by the change in absolute neutrophil count after 12 months of treatment compared to the period before study
|
1 year
|
Occurrence of hypoglycemia
Time Frame: 1 year
|
Safety and tolerability of Empaglifozin measured by hypoglycemia
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of infections
Time Frame: 1 year
|
Efficacy of Empaglifozin measured by the number of respiratory tract, skin, and urinary tract infections
|
1 year
|
Inflammatory bowel disease activity
Time Frame: 1 year
|
Measured as classical Crohn 's disease activity index (CDAI) for adults (range from 0 to 600; remission <150; mildly active disease 150-219; moderately active disease 220- 450; severely active disease ≥ 450) or pediatric Crohn' s disease activity index (PCDAI) for children (range from 0 to 100; remission <10; mildly active disease 10-27.5;
moderately active disease 30-37.5;
severely active disease 40-100) after 3, 6, 9, and 12 months of treatment compared to the period before study
|
1 year
|
Endoscopic scores of inflammatory bowel disease
Time Frame: 1 year
|
Measured as difference in Crohn 's Disease Simplified Endoscopic Score (SES-CD) (range from 0 to 17; remission 0-2; mild endoscopic activity 3-6; moderate endoscopic activity 7-15; severe endoscopic activity >15) before and after 1 year of empagliflozin treatment
|
1 year
|
Change of triglycerides
Time Frame: 1 year
|
Measured as change of triglycerides (mmol/L) compared to the period before study
|
1 year
|
Change of total cholesterol
Time Frame: 1 year
|
Measured as change of total cholesterol (mmol/L) compared to the period before study
|
1 year
|
Change of lactate
Time Frame: 1 year
|
Measured as change of lactate (mmol/L) compared to the period before study
|
1 year
|
Change of uric acid
Time Frame: 1 year
|
Measured as change of uric acid (mmol/L) compared to the period before study
|
1 year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Wenjuan Qiu, MD PhD, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Metabolic Diseases
- Genetic Diseases, Inborn
- Carbohydrate Metabolism, Inborn Errors
- Metabolism, Inborn Errors
- Disease
- Glycogen Storage Disease
- Glycogen Storage Disease Type I
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Sodium-Glucose Transporter 2 Inhibitors
- Empagliflozin
Other Study ID Numbers
- XHEC-C-2023-051-2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glycogen Storage Disease Type IB
-
John MitchellCompletedGlycogen Storage Disease Type III | Glycogen Storage Disease Type IA | Glycogen Storage Disease Type IB | Glycogen Storage Disease Type 0Canada
-
Sanguine BiosciencesTerminatedGlycogen Storage Disease Type IBUnited States
-
Duke UniversityKriya TherapeuticsRecruitingGlycogen Storage Disease VI | GLYCOGEN STORAGE DISEASE IXa1 | GLYCOGEN STORAGE DISEASE IXa2 | Glycogen Storage Disease IXB | Glycogen Storage Disease IXC | GSD 9 (All Subtypes) | GSD 6United States
-
University Medical Center GroningenUltragenyx Pharmaceutical IncCompletedGlycogen Storage Disease Type IANetherlands
-
CENTOGENE GmbH RostockWithdrawnFructose Metabolism, Inborn Errors | Glycogen Storage Disease Type II | Glycogen Storage Disease | Glycogen Storage Disease Type V | Glycogen Storage Disease Type I | Glycogen Storage Disease Type III | Glycogen Storage Disease Type VII | Glycogen Storage Disease Type IV | Glycogen Storage Disease Type... and other conditionsGermany, India, Sri Lanka
-
Ultragenyx Pharmaceutical IncActive, not recruitingGlycogen Storage Disease Type IAUnited States, Brazil, Canada, Denmark, Germany, Italy, Netherlands, Spain
-
Hong Kong Children's HospitalRecruitingGlycogen Storage Disease Type IBHong Kong
-
Ultragenyx Pharmaceutical IncCompletedGlycogen Storage Disease Type IANetherlands, United States
-
Ultragenyx Pharmaceutical IncActive, not recruitingGlycogen Storage Disease Type IA | Von Gierke's Disease (GSD Type Ia)Netherlands, United States, Canada, Spain
-
University of ManitobaCo-Investigator - Dr. Cheryl Rockman-GreenbergCompletedHypoglycemia | Glycogen Storage Disorder Type 1 | Cornstarch | GlycosadeCanada
Clinical Trials on Empagliflozin
-
Boehringer IngelheimEli Lilly and CompanyCompletedDiabetes Mellitus, Type 1Austria, Germany
-
University Medical Centre LjubljanaUnknownDiabetes Complications | Diabetes Mellitus, Type 1 | Vascular Stiffness | Hypoglycemic AgentsSlovenia
-
Boehringer IngelheimEli Lilly and CompanyCompletedDiabetes Mellitus, Type 1Japan
-
Boehringer IngelheimEli Lilly and CompanyCompletedDiabetes Mellitus, Type 2United States, Australia, Canada, Estonia, France, Georgia, Germany, Guatemala, Italy, Latvia, Lithuania, Mexico, New Zealand, Poland, Russian Federation, South Africa, Spain, Ukraine
-
Boehringer IngelheimEli Lilly and CompanyCompletedDiabetes Mellitus, Type 2United States, France, Israel, Mexico, South Africa
-
Boehringer IngelheimEli Lilly and CompanyCompleted
-
Boehringer IngelheimEli Lilly and CompanyCompleted
-
Boehringer IngelheimCompleted
-
Dong-A ST Co., Ltd.CompletedType2 DiabetesKorea, Republic of
-
Collegium Medicum w BydgoszczyRecruitingMetabolic SyndromePoland